Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

BioMarin Pharma. News

Aktie
WKN:  924801 ISIN:  US09061G1013 US-Symbol:  BMRN Branche:  Biotechnologie Land:  USA
45,94 €
-0,1 €
-0,22%
19:31:38 Uhr
Depot/Watchlist
Marktkapitalisierung *
9,78 Mrd. €
Streubesitz
1,13%
KGV
16,80
Index-Zuordnung
Nasdaq Composite Index

BioMarin Pharmaceutical News

06.09.25 - PR Newswire
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-​pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of ...
27.08.25 - PR Newswire
BioMarin to Participate in Upcoming Investor Conferences
BioMarin to Participate in Upcoming Investor Conferences PR Newswire
04.08.25 - PR Newswire
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS PR Newswire
01.08.25 - PR Newswire
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
BioMarin Announces Appointment of Ian T. Clark to Board of Directors PR Newswire
22.07.25 - PR Newswire
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET PR Newswire
01.07.25 - PR Newswire
BioMarin Announces Completion of Acquisition of Inozyme
BioMarin Announces Completion of Acquisition of Inozyme PR Newswire
24.06.25 - PR Newswire
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-​rvox) at International Society on Thrombosis ...
16.05.25 - PR Newswire
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma PR Newswire
12.05.25 - PR Newswire
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings PR Newswire
01.05.25 - PR Newswire
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance PR Newswire
17.04.25 - PR Newswire
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET PR Newswire
02.04.25 - PR Newswire
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-​pqpz) in Adolescents with Phenylketonuria PR Newswire
20.03.25 - PR Newswire
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-​World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with ...
25.02.25 - PR Newswire
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA PR Newswire
24.02.25 - PR Newswire
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors PR Newswire
19.02.25 - PR Newswire
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance PR Newswire
05.02.25 - PR Newswire
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET PR Newswire
13.01.25 - PR Newswire
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court PR Newswire
06.01.25 - PR Newswire
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA PR Newswire
16.11.24 - PR Newswire
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
BioMarin Presents Real-​World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric ...

Newssuche

Videos

newspaper
16.04.26 +3,07%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »